ARD Podcast
Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal committed to promoting the highest standards of scientific exchange and education. It covers all aspects of rheumatology, which includes the spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research. Concise scientific communication is encouraged and peer-reviewed proceedings of international meetings are featured. ARD is the official journal of EULAR.
Episodes
This podcast brings you the 2023 update on the EULAR recommendations for the management of systemic lupus erythematosus (SLE).
ARD's Social Media Advisor, Professor Laura Andreoli, speaks to Professors Antonios Fanouriakis and Dimitrios Boumpas, both from the "Attikon" University Hospital, National and Kapodistrian University of Athens, Greece, two of the authors of the recommendations paper. Read it on the ARD website: https://ard...
In this podcast, we discuss the evidence-based EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). ARD's Social Media Advisor, Professor Laura Andreoli, speaks to Professor Carina Boström and Professor Ioannis Parodis, both from the Karolinska Institutet and the Karolinska University Hospital, Stockholm, Sweden, about their recent paper. Read it on the ARD...
In this podcast, ARD’s social media editor, Dr Paul Studeni...
Read the paper: ard.bmj.com/content/78/9/1242
Hensvold et al. developed a prediction score by combining several clinical and blood-based markers that could be useful in predicting which patients with auto-antibodies and musculoskeletal ...
Dr. Felice Rivellese from the Center of Experimental Medicine and Rheumatology at the Queen Mary University in London discusses the results of his presentation at the ACR 2019 with Dr. Caroline Ospelt. In a subanalysis of the pathobiology of the Early Arthitis Cohort (PEAC), Rivellese at al could show that B cell-rich synovitis is associated with disease severity and radiographic progression, in particular, if B cell infiltrates pe...
This randomised, double-blind, placebo-controlled trial by Kroon et al has demonstrated a substantial improvement in painful hand OA with signs of inflammation following six weeks of low-dose prednisolone.
Atul Deodhar, from the Oregon Health & Science University, provides an overview of recent clinical trial results in the area of seronegative Spondylarthritis. He presented the 24-week data of Guselkumab in active psoriatic arthritis patients in the DISCOVER-1 study and compared the phase 3 trials in non-radiographic SpA patients on Ixekizumab (COAST-X) and Secukinumab (PREVENT) with up to 52 week data available.
In this second phase 3 trial, the primary endpoint, BICLA, was achieved, and anifrolumab was superior to placebo for multiple secondary efficacy endpoints, including SRI(4), skin disease, and oral corticosteroid tapering.
In this first phase 3 trial, the primary endpoint, SRI(4), was not achieved, but numeric improvements achieving thresholds associated with clinical benefit were observed for BICLA, oral corticosteroid tapering and other organ-specific endpoints.
Read the full paper on the ARD website: https://ard.bmj.com/content/78/6/736.
Submit your manuscript here: https://mc.manuscriptcentral.com/ard.
Popular Podcasts
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations.
Anna Sale explores the big questions and hard choices that are often left out of polite conversation.
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
If you can never get enough true crime... Congratulations, you’ve found your people.
A straightforward look at the day's top news in 20 minutes. Powered by ABC News. Hosted by Brad Mielke.